2021
Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children's Oncology Group
Parikh RR, Kelly KM, Hodgson DC, Hoppe BS, McCarten KM, Karolczuk K, Pei Q, Wu Y, Cho SY, Schwartz C, Cole PD, Roberts K. Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children's Oncology Group. International Journal Of Radiation Oncology • Biology • Physics 2021, 112: 890-900. PMID: 34767937, PMCID: PMC9038118, DOI: 10.1016/j.ijrobp.2021.10.152.Peer-Reviewed Original ResearchConceptsInvolved-field radiation therapySlow early responseClassical Hodgkin lymphomaBulky diseaseOncology GroupHodgkin's lymphomaRetrospective analysisChildren's Oncology Group protocolsHigh-risk Hodgkin lymphomaRadiation treatment volumesCycles of doxorubicinHigh-risk patientsPhase 3 studyTime of progressionChildren's Oncology GroupPatterns of failureInitial siteABVE-PCConsolidation RTEligible patientsField relapseInitial relapseMedian followRelapse siteStage IIIB
2019
Mouse cytomegalovirus-experienced ILC1s acquire a memory response dependent on the viral glycoprotein m12
Weizman O, Song E, Adams N, Hildreth A, Riggan L, Krishna C, Aguilar O, Leslie C, Carlyle J, Sun J, O’Sullivan T. Mouse cytomegalovirus-experienced ILC1s acquire a memory response dependent on the viral glycoprotein m12. Nature Immunology 2019, 20: 1004-1011. PMID: 31263280, PMCID: PMC6697419, DOI: 10.1038/s41590-019-0430-1.Peer-Reviewed Original ResearchConceptsInnate lymphoid cellsTissue-resident innate lymphoid cellsType 1 innate lymphoid cellsMouse cytomegalovirusMemory lymphocyte responsesResolution of infectionTissue-resident sentinelsPathogen-derived antigensEarly host protectionLymphocyte responsesBystander activationProinflammatory cytokinesHeterologous infectionsMCMV infectionEffector responsesSecondary challengeHost protectionLymphoid cellsMemory responsesInfectionInitial sitePresent studyPhenotypic changesResponseILC1s
2014
The Nogo Receptor NgR1 Mediates Infection by Mammalian Reovirus
Konopka-Anstadt JL, Mainou BA, Sutherland DM, Sekine Y, Strittmatter SM, Dermody TS. The Nogo Receptor NgR1 Mediates Infection by Mammalian Reovirus. Cell Host & Microbe 2014, 15: 681-691. PMID: 24922571, PMCID: PMC4100558, DOI: 10.1016/j.chom.2014.05.010.Peer-Reviewed Original ResearchConceptsCentral nervous systemReceptor NgR1Reovirus infectionExpression of NgR1Primary cortical neuronsDistinct cell surface moleculesJunctional adhesion molecule ASoluble NgR1Cell surface moleculesNeurotropic virusesCortical neuronsMammalian reovirusesNonsusceptible cellsNervous systemNgR1Null miceSystemic spreadInfectionIndependent receptorsMultiple receptorsReovirus replicationInitial siteReovirus virionsNeuronsReceptors
2005
High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib
Omuro AM, Kris MG, Miller VA, Franceschi E, Shah N, Milton DT, Abrey LE. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer 2005, 103: 2344-2348. PMID: 15844174, DOI: 10.1002/cncr.21033.Peer-Reviewed Original ResearchConceptsNonsmall cell lung carcinomaCentral nervous systemDisease recurrenceLong-term outcomesCell lung carcinomaBrain metastasesCNS metastasesLeptomeningeal metastasesLung carcinomaHigh incidenceAdvanced nonsmall cell lung carcinomaEpidermal growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsMedian Karnofsky performance scoreMemorial Sloan-Kettering Cancer CenterMedian overall survival periodReceptor tyrosine kinase inhibitorsInitial disease recurrenceKarnofsky performance scoreOverall survival periodInitial responseTyrosine kinase inhibitorsInitial siteNeurologic symptomsPartial response
1975
Results of combination chemotherapy of non-Hodgkin's lymphoma.
Schein P, Chabner B, Canellos G, Young R, Berard C, DeVita V. Results of combination chemotherapy of non-Hodgkin's lymphoma. British Journal Of Cancer. Supplement 1975, 2: 465-73. PMID: 1101932, PMCID: PMC2149606.Peer-Reviewed Original ResearchConceptsComplete remissionHodgkin's lymphomaCombination chemotherapyHistological subgroupsLymphocytic lymphomaMonths of treatmentDiffuse histiocytic lymphomaMOPP chemotherapyMedian durationLate recurrenceLymph nodesNodular histologyHistiocytic lymphomaRemissionExtended survivalBone marrowClinical validityLymphomaAdvanced stageChemotherapyPatientsRelapseInitial siteMonthsSurvivalNon‐Hodgkin's lymphoma: Patterns of relapse from complete remission after combination chemotherapy
Schein P, Chabner B, Canellos G, Young R, Devita V. Non‐Hodgkin's lymphoma: Patterns of relapse from complete remission after combination chemotherapy. Cancer 1975, 35: 354-357. PMID: 1089470, DOI: 10.1002/1097-0142(197502)35:2<354::aid-cncr2820350209>3.0.co;2-2.Peer-Reviewed Original ResearchConceptsDiffuse histiocytic lymphomaComplete remissionLymphocytic lymphomaCombination chemotherapyHistiocytic lymphomaExtended disease-free survivalDisease-free survivalPatterns of relapseMonths of treatmentMaintenance chemotherapyRemission inductionLymph nodesLate recurrenceHistologic subgroupsHodgkin's lymphomaRemissionBone marrowLymphomaChemotherapyAggressive attemptsPatientsRelapseInitial siteTreatmentRecurrence
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply